JUN 02, 2021 10:30 AM PDT

Keynote Presentation: New Checkpoints and Biomarkers

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Inhibitory signals through the PD-1 pathway regulate T cell activation, tolerance, and exhaustion. To study the role of PD-1 in Treg cells, we generated mice that selectively lack PD-1 in T reg cells. PD-1–deficient Treg cells exhibit an activated phenotype and enhanced immunosuppressive function. The potent suppressive capacity of PD-1–deficient Treg is illustrated by protection from diabetes in NOD mice and ameliorated  EAE in mice lacking PD-1 selectively in Treg cells. Reduced PI3K–AKT pathway signaling is a mechanism underlying enhanced suppressive capacity of PD-1–deficient Treg. Our results show PD-1 is an “equal-opportunity” inhibitor of T cell activities. When PD-1 is lost on cells whose primary function is to suppress immune responses, the consequence is a stronger suppressor cell. This means that the outcome of PD-1 pathway blockade in vivo is a summation of increased Teffector and enhanced Treg suppressive activities.  The consequences for CTLA-4 combination therapy and for hyperprogression will be discussed. The frequency of PD-1+CD8+ T cells to PD-1+ Treg in the tumor microenvironment is a potential biomarker of PD-1 efficacy. Additional immune inhibitory pathways contribute to tumor immune evasion. HHLA2, a member of the B7 family of immunoregulatory ligands, has costimulatory effects through the CD28 family member TMIGD2, but HHLA2 also has inhibitory effects on T cells. We identified KIR3DL3 as an inhibitory receptor for HHLA2 in T and NK cells. We generated HHLA2 and KIR3DL3 antibodies that block the immune inhibitory activity of HHLA2 and enhance T cell and NK activities, preserving the costimulatory signal. HHLA2 is frequently expressed in several tumor types including clear cell renal cell carcinoma (ccRCC). HHLA2 expression was non-overlapping with PD-L1 expression, suggesting that HHLA2 mediates a mechanism of tumor immune evasion that is independent from PD-L1. Blockade of both PD-1 and KIR3DL3 pathways may be a more effective way to reverse tumor immune evasion.

Learning Objectives:

1. Understand how the outcome of PD-1 blockade is a summation of increased Teffector activity and increased Treg suppressive activity

2. Explain how PD-1 blockade leads to increased T reg activity

3. Understand a new checkpoint pathway, HHLA2-KIR3DL3


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
MAR 18, 2021 8:00 AM PDT
C.E. CREDITS
MAR 18, 2021 8:00 AM PDT
DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
Loading Comments...
Show Resources